Eli Lilly and Co
LLY738.210USD
-50.990-6.46%
收盤 04/04, 16:00（美東）報價延遲15分鐘
699.48B總市值
66.05本益比TTM
關於 Eli Lilly and Co 公司
禮來公司是一家制藥公司。該公司在人類藥品領域發現、開發、製造和銷售產品。其糖尿病、肥胖症和其他心臟代謝產品包括 Basaglar、Humalog、Mounjaro、Trulicity 和 Zepbound。其腫瘤產品包括 Alimta、Retevmo、Tyvyt 和 Verzenio。其免疫學產品包括 Ebglyss、Olumiant、Omvoh 和 Taltz。其神經科學產品包括 Cymbalta 和 Emgality。其其他產品和療法包括 Cialis 和 Forteo。該公司通過位於美國（包括波多黎各）以及歐洲和亞洲的工廠生產和分銷其產品。該公司通過其子公司 POINT Biopharma Global Inc. 從事放射性藥物的發現、開發和製造，以及臨牀和臨牀前放射性配體療法。該公司還在開發用於治療炎症性腸病 (IBD) 的 α4β7 整合素口服小分子抑制劑 (稱爲 MORF-057)。
公司簡介
公司代碼LLY
公司名稱Eli Lilly and Co
上市日期Jul 09, 1970
成立日期1901
CEOMr. David A. (Dave) Ricks
員工數量47000
證券類型Ordinary Share
年結日Jul 09
公司地址Lilly Corporate Ctr
城市INDIANAPOLIS
上市交易所NYSE Consolidated
國家United States of America
郵編46285
電話13172762000
網址https://www.lilly.com/
公司代碼LLY
上市日期Jul 09, 1970
成立日期1901
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
212.28K
+12.97%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
72.69K
+0.02%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
43.54K
+175.92%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.75K
+4.13%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
28.76K
+45.24%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.16K
+0.62%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+77.63%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
13.97K
+26.18%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
212.28K
+12.97%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
72.69K
+0.02%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
43.54K
+175.92%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.75K
+4.13%
收入明細
單位: USD更新時間: 4月2日 週三
單位: USD更新時間: 4月2日 週三
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Diabetes-Mounjaro
11.54B
25.62%
Oncology-Verzenio
5.31B
11.78%
Diabetes-Trulicity
5.25B
11.66%
Diabetes-Zepbound
4.93B
10.94%
Diabetes-Jardiance
3.34B
7.42%
Other
14.68B
32.58%
地區USD
名稱
營收
佔比
U.S.
30.38B
67.44%
Europe
6.92B
15.36%
Other foreign countries
4.27B
9.48%
Japan
1.81B
4.03%
China
1.66B
3.69%
業務
地區
業務USD
名稱
營收
佔比
Diabetes-Mounjaro
11.54B
25.62%
Oncology-Verzenio
5.31B
11.78%
Diabetes-Trulicity
5.25B
11.66%
Diabetes-Zepbound
4.93B
10.94%
Diabetes-Jardiance
3.34B
7.42%
Other
14.68B
32.58%
股東統計
更新時間: 2月21日 週五
更新時間: 2月21日 週五
持股股東
股東類型
持股股東
股東統計
佔比
Lilly Endowment, Inc.
10.13%
The Vanguard Group, Inc.
7.80%
PNC Investments LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.62%
Other
68.73%
持股股東
股東統計
佔比
Lilly Endowment, Inc.
10.13%
The Vanguard Group, Inc.
7.80%
PNC Investments LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.62%
Other
68.73%
股東類型
股東統計
佔比
Investment Advisor
37.91%
Investment Advisor/Hedge Fund
25.90%
Foundation
10.22%
Research Firm
1.93%
Pension Fund
1.88%
Bank and Trust
1.79%
Insurance Company
1.43%
Sovereign Wealth Fund
1.24%
Hedge Fund
1.10%
Other
16.61%
機構持股
更新時間: 2月20日 週四
更新時間: 2月20日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
5515
795.05M
83.86%
+1.55M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
2023Q2
4197
799.48M
84.22%
-4.32M
2023Q1
4061
801.36M
84.15%
-9.39M
2022Q4
3985
805.64M
84.79%
-7.51M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Lilly Endowment, Inc.
96.02M
10.13%
-220.00K
-0.23%
Mar 03, 2025
The Vanguard Group, Inc.
73.90M
7.8%
+486.78K
+0.66%
Dec 31, 2024
PNC Investments LLC
51.08M
5.39%
-49.68K
-0.10%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
41.11M
4.34%
+29.75K
+0.07%
Dec 31, 2024
State Street Global Advisors (US)
34.31M
3.62%
+461.69K
+1.36%
Dec 31, 2024
Fidelity Management & Research Company LLC
29.35M
3.1%
-2.42M
-7.60%
Dec 31, 2024
T. Rowe Price Associates, Inc.
19.73M
2.08%
-77.25K
-0.39%
Dec 31, 2024
Capital World Investors
19.55M
2.06%
-803.44K
-3.95%
Dec 31, 2024
Geode Capital Management, L.L.C.
17.38M
1.83%
+291.88K
+1.71%
Dec 31, 2024
PRIMECAP Management Company
16.76M
1.77%
-933.85K
-5.28%
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月2日 週三
更新時間: 4月2日 週三
機構名稱
佔比
Defiance Daily Target 2X Long LLY ETF
30.83%
iShares U.S. Pharmaceuticals ETF
25.29%
Amplify Weight Loss Drug & Treatment ETF
18.44%
Roundhill GLP-1 & Weight Loss ETF
18.11%
VanEck Pharmaceutical ETF
14.74%
Proshares Ultra Health Care
13.36%
Health Care Select Sector SPDR Fund
13.35%
iShares U.S. Healthcare ETF
13.16%
Fidelity MSCI Health Care Index ETF
11.93%
Simplify Health Care ETF
11.07%
查看更多
Defiance Daily Target 2X Long LLY ETF
佔比30.83%
iShares U.S. Pharmaceuticals ETF
佔比25.29%
Amplify Weight Loss Drug & Treatment ETF
佔比18.44%
Roundhill GLP-1 & Weight Loss ETF
佔比18.11%
VanEck Pharmaceutical ETF
佔比14.74%
Proshares Ultra Health Care
佔比13.36%
Health Care Select Sector SPDR Fund
佔比13.35%
iShares U.S. Healthcare ETF
佔比13.16%
Fidelity MSCI Health Care Index ETF
佔比11.93%
Simplify Health Care ETF
佔比11.07%
分紅派息
近5年累計派現
18.06B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
Jun 26, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023
Aug 15, 2023
Sep 08, 2023
Aug 14, 2023
May 01, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Jun 09, 2023 going ex on May 12, 2023
May 15, 2023
Jun 09, 2023
May 12, 2023
Dec 12, 2022
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 10, 2023 going ex on Feb 14, 2023
Feb 15, 2023
Mar 10, 2023
Feb 14, 2023
Oct 17, 2022
LLY.NB Final Cash Dividend of gross USD 0.98 paid on Dec 09, 2022 going ex on Nov 14, 2022
Nov 15, 2022
Dec 09, 2022
Nov 14, 2022
查看更多
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據